<DOC>
	<DOCNO>NCT00782210</DOCNO>
	<brief_summary>This primary objective study compare two dos BI 1744 CL inhalation solution deliver RespimatÂ® inhaler daily placebo patient chronic obstructive pulmonary disease ( COPD ) . The safety BI 1744 CL inhalation solution deliver Respimat inhaler also compare placebo .</brief_summary>
	<brief_title>12 / 48 Week Pivotal PFT v PBO COPD I</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Inclusion criterion : All patient must diagnosis chronic obstructive pulmonary disease Male female patient , 40 year age old Patients must current exsmokers smoke history 10 pack year Post bronchodilator FEV1 &lt; 80 % predict postbronchodilator FEV1/FVC &lt; 70 % Exclusion criterion : Patients significant disease COPD Patients history asthma Patients follow condition : history myocardial infarction within 1 year screen visit ( Visit 1 ) unstable lifethreatening cardiac arrhythmia . hospitalize heart failure within past year . know active tuberculosis malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( patient treat basal cell carcinoma allow ) history lifethreatening pulmonary obstruction history cystic fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>